{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:27:55Z","timestamp":1772944075895,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-75-00160"],"award-info":[{"award-number":["24-75-00160"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcyt.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:26:49Z","timestamp":1755620809000},"page":"1384-1395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-1373","authenticated-orcid":false,"given":"Rodion A.","family":"Velichinskii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-0753","authenticated-orcid":false,"given":"Maria A.","family":"Streltsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9075-218X","authenticated-orcid":false,"given":"Julia D.","family":"Vavilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna A.","family":"Boyko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-4078","authenticated-orcid":false,"given":"Tatyana N.","family":"Belovezhets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Grechikhina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena I.","family":"Kovalenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.08.001_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0002","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0003","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0004","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091868","article-title":"Natural killer cells: angels and devils for immunotherapy","volume":"18","author":"Mart\u00edn-Antonio","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174318","article-title":"Current progress of CAR-NK therapy in cancer treatment","volume":"14","author":"Pang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111385","article-title":"The biological role and therapeutic potential of NK cells in hematological and solid tumors","volume":"22","author":"Velichinskii","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.03038","article-title":"Influence of the tumor microenvironment on NK cell function in solid tumors","volume":"10","author":"Melaiu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-infiltrating natural killer cells","volume":"11","author":"C\u00f3zar","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0014","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nri3065","article-title":"Organ-specific features of natural killer cells","volume":"11","author":"Shi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0015","article-title":"Distinct signatures in the receptor repertoire discriminate CD56bright and CD56dim","volume":"11","author":"Schwane","year":"2020","journal-title":"Natural Killer Cells. Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0016","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0017","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"he","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0018","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0019","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","article-title":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity","volume":"101","author":"Fehniger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri2297","article-title":"CCR7 and its ligands: balancing immunity and tolerance","volume":"8","author":"F\u00f6rster","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0021","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/blood-2011-11-389924","article-title":"Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7","volume":"119","author":"Somanchi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0022","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","article-title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma","volume":"24","author":"Schomer","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CAD.0000000000000868","article-title":"Overexpressed CXCR4 and CCR7 on the surface of NK92 cell have improved migration and anti-tumor activity in human colon tumor model","author":"Yang","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00262-014-1629-5","article-title":"CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo","volume":"64","author":"Wennerberg","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0025","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","article-title":"Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands","volume":"68","author":"Wendel","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0026","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0027","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood.V97.2.367","article-title":"Expression and regulation of chemokine receptors in human natural killer cells","volume":"97","author":"Inngjerdingen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0028","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.4049\/jimmunol.177.11.7833","article-title":"Evidence for NK cell subsets based on chemokine receptor expression","volume":"177","author":"Berahovich","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0029","first-page":"2015","article-title":"Chemokine receptor expression on normal blood CD56(+) NK-cells elucidates cell partners that comigrate during the innate and adaptive immune responses and identifies a transitional NK-cell Population","author":"Lima","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK Cells in Mice with peritoneal xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0031","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2010-04-277897","article-title":"CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice","volume":"117","author":"Noda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0032","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2019.01262","article-title":"Enhanced bone marrow homing of natural killer cells following mRNA transfection with gain-of-function variant CXCR4R334X","volume":"10","author":"Levy","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0033","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2020.02028","article-title":"Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4","volume":"11","author":"Jamali","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0034","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML","volume":"24","author":"Bjorklund","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0036","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0037","unstructured":"Prostate cancer statistics, World Cancer Research Fund n.d. https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/prostate-cancer-statistics\/(accessed April 10, 2025)."},{"key":"10.1016\/j.jcyt.2025.08.001_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-0183-x","article-title":"PSCA is a target of chimeric antigen receptor T cells in gastric cancer","volume":"8","author":"Wu","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0039","first-page":"3081","article-title":"Prostate stem cell antigen is expressed in normal and malignant human brain tissues","volume":"15","author":"Ono","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-024-03320-6","article-title":"Significance of PSCA as a novel prognostic marker and therapeutic target for cancer","volume":"24","author":"Nayerpour Dizaj","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0041","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1477-2574.2011.00344.x","article-title":"Engineered T cells for pancreatic cancer treatment","volume":"13","author":"Katari","year":"2011","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0042","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0043","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0044","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1134\/S1068162017020091","article-title":"Modular lentiviral vector system for chimeric antigen receptor design optimization","volume":"43","author":"Kulemzin","year":"2017","journal-title":"Russ J Bioorg Chem"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0047","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0049","doi-asserted-by":"crossref","first-page":"70","DOI":"10.18620\/ctt-1866-8836-2018-7-2-70-77","article-title":"Analysis of in vitro activity of PSCA-specific CARs in the context of human NK cell line YT","volume":"7","author":"Matvienko","year":"2018","journal-title":"Cell Ther Transplant"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0050","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0051","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-09-3169","article-title":"Prostate stem cell antigen: A Jekyll and Hyde molecule?","volume":"16","author":"Saeki","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0052","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0053","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12935-024-03320-6","article-title":"Significance of PSCA as a novel prognostic marker and therapeutic target for cancer","volume":"24","author":"Nayerpour Dizaj","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0054","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/JP9.0000000000000154","article-title":"PSCA is a critical biomarker for predicting the prognosis of KRAS\/TP53 mutant pancreatic cancer patients","volume":"7","author":"Gong","year":"2024","journal-title":"J Pancreatol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0055","doi-asserted-by":"crossref","first-page":"54592","DOI":"10.18632\/oncotarget.17523","article-title":"Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2\/neu overexpression","volume":"8","author":"Link","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0058","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0059","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","article-title":"TNF-\u03b1\/NF-\u03baB\/Snail pathway in cancer cell migration and invasion","volume":"102","author":"Wu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0060","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1038\/emm.2016.64","article-title":"Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types","volume":"48","author":"Hong","year":"2016","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0061","doi-asserted-by":"crossref","first-page":"185.5","DOI":"10.4049\/jimmunol.194.Supp.185.5","article-title":"Dual roles of GM-CSF in modulating NK-cell migratory properties (CAM4P.147)","volume":"194","author":"Andalur Nandagopal","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0063","first-page":"860","article-title":"Killing effect of Robo1 targeted chimeric antigen receptor modified NK92 cells against glioma and neuroblastoma cells","volume":"98","author":"Qu","year":"2018","journal-title":"National Medical Journal of China"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0064","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3892\/or.2013.2516","article-title":"The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer","volume":"30","author":"He","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.03038","article-title":"Influence of the tumor microenvironment on NK cell function in solid tumors","volume":"10","author":"Melaiu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/839684","article-title":"Chemokine receptor expression on normal blood CD56+ NK-cells elucidates cell partners that comigrate during the innate and adaptive immune responses and identifies a transitional NK-cell population","volume":"2015","author":"Lima","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051677","article-title":"Human natural killer cell maturation defect supports in vivo CD56bright to CD56dim lineage development","volume":"7","author":"Domaica","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0068","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0069","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.imlet.2012.04.014","article-title":"Chemokines and NK cells: regulators of development, trafficking and functions","volume":"145","author":"Bernardini","year":"2012","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","article-title":"Chemokine networks modulating natural killer cell trafficking to solid tumors","volume":"59","author":"Yao","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0071","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1134\/S1607672922340142","article-title":"Subpopulation heterogeneity of NK cells during the genetic modification for subsequent use in targeted therapy","volume":"507","author":"Streltsova","year":"2022","journal-title":"Dokl Biochem Biophys"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0072","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2016.00414","article-title":"Human NK cell subsets redistribution in pathological conditions: A role for CCR7 receptor","volume":"7","author":"Pesce","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2015.05.003","article-title":"Chemokine-guided cell positioning in the lymph node orchestrates the generation of adaptive immune responses","volume":"36","author":"Lian","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0074","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/blood-2011-11-389924","article-title":"Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7","volume":"119","author":"Somanchi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.semcdb.2015.01.008","article-title":"The lymph node microenvironment and its role in the progression of metastatic cancer","volume":"38","author":"Pereira","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0076","first-page":"4176","article-title":"Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer","volume":"18","author":"Bi","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0077","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0078","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa012","article-title":"Clinical and functional characterization of CXCR1\/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma","volume":"2","author":"Armstrong","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0079","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"CXCR3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.intimp.2018.07.026","article-title":"CXCR3-deficient natural killer cells fail to migrate to B16F10 melanoma cells","volume":"63","author":"J","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0081","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneuroim.2008.04.029","article-title":"Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation","volume":"199","author":"Maru","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0082","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1158\/0008-5472.CAN-06-0709","article-title":"Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer","volume":"66","author":"Walser","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0083","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-03-1757","article-title":"Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes","volume":"64","author":"Kawada","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0084","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/sj.onc.1210267","article-title":"Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes","volume":"26","author":"Kawada","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0085","first-page":"1","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0087","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy: advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0089","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.omtm.2023.08.017","article-title":"Development of an in vitro genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants","volume":"30","author":"Bastone","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.08.001_bib0090","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","article-title":"Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy","volume":"27","author":"Wu","year":"2022","journal-title":"Mol Ther Oncolytics"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:10:07Z","timestamp":1772889007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":90,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1465324925008072"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.08.001","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}